Cross-Sector entity
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Amprius Technologies, the most common co-covered peer. We currently track 1 Cross-Sector story that mention Elritercept, all published on March 4, 2026.
1 verified story tracked
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Amprius Technologies, the most common co-covered peer. We currently track 1 Cross-Sector story that mention Elritercept, all published on March 4, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Elritercept. Shared-story counts are live from our verified record — not editorial picks.
FY 2025 Earnings
Released full-year financial results and updated 2026 clinical guidance.
Anticipated Data
Expected top-line data readouts for multiple Phase 2 programs.
Cibotercept Progress
Initiated additional cohorts in PAH studies to evaluate dose-response.
Trial Expansion
Keros expanded the TROPOS trial to include broader MDS patient populations.
Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.
Source: lasvegassun.com · manilatimes.net
